![Public Storage](/common/images/company/TG_PUP.png)
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024OK-101 is believed to be the first IND clearance granted by FDA for a drug to...
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye...
LONDON and NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
LONDON and NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
LONDON and NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
LONDON and NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.70001 | 0.253259777614 | 276.39999 | 281.39999 | 271.1 | 33 | 275.64011754 | DE |
4 | 12.9 | 4.88266464799 | 264.2 | 288.7 | 263.6 | 61 | 276.06761192 | DE |
12 | 20.5 | 7.98908807482 | 256.6 | 288.7 | 241.5 | 77 | 264.57220198 | DE |
26 | 13.6 | 5.16129032258 | 263.5 | 288.7 | 240.3 | 102 | 260.63159826 | DE |
52 | 20.6 | 8.03118908382 | 256.5 | 288.7 | 220.5 | 109 | 256.80935509 | DE |
156 | 20.6 | 8.03118908382 | 256.5 | 288.7 | 220.5 | 109 | 256.80935509 | DE |
260 | 91.84 | 49.5735722768 | 185.26 | 288.7 | 182.78 | 107 | 256.04801511 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.